Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Novadoz Pharmaceuticals Wins Approval for Several New Products in 2022 Including Products Manufactured in its new US based plant
Tuesday, August 16, 2022Novadoz Pharmaceuticals is pleased to announce the launch of several new products to add to its diverse portfolio of generic medicines Products launched include Also Novadoz is launching three new oral solutions out of its new stateoftheart manufactu...
Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022
Monday, August 15, 2022Lytix Biopharma AS a clinicalstage company with an in situ vaccination technology platform announces that an abstract relating to LTX in combination with Adoptive Cell Therapy ACT has been selected for presentation at a Poster Session during American...
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
Monday, August 15, 2022Chemomab Therapeutics Ltd a clinicalstage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need today announced the addition of Ilan Vaknin PhD MBA as Vic...
Harm Reduction Therapeutics Signs Commercial Supply Agreement for Fast Tracked Naloxone Nasal Spray to Reverse Opioid Overdoses
Thursday, August 11, 2022Harm Reduction Therapeutics HRT Inc a c nonprofit pharmaceutical company whose mission is to prevent opioid overdose deaths by making free or lowcost overthecounter OTC naloxone available to everyone today announced the signing of a commercial supply...
Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space
Wednesday, August 10, 2022Aquestive Therapeutics Inc a pharmaceutical company advancing medicines to solve patients problems with current standards of care and provide transformative products to improve their lives announced today the appointments of Timothy E Morris to the C...
OceanTech Acquisitions I Corp. and Captura Biopharma, Inc. Announce Signing of Definitive Business Combination Agreement
Wednesday, August 10, 2022Captura Biopharma an emerging biotechnology company developing and commercializing oral chelators to treat internal transuranic radionuclide contamination and heavy metal poisoning and OceanTech Acquisitions I Corp a special purpose acquisition compa...
New England Biolabs® Introduces Faustovirus Capping Enzyme, a Novel Enzymatic mRNA Capping Solution for mRNA Manufacturing
Tuesday, August 09, 2022Today New England Biolabs NEB announces the release of the Faustovirus Capping Enzyme FCE an mRNA capping solution that combines high activity and a broad temperature range to support mRNA therapeutic manufacturing needs As a singlesubunit enzyme FCE...
Fresenius Kabi, a Leader in Injectable Medicines, Introduces Data Matrix Barcodes on all Drugs as part of Companywide Commitment to Medication Safety
Monday, August 08, 2022Fresenius Kabi announced today the introduction of a threeyear plan to add GS Data Matrix barcodes to its pharmaceutical portfolio of vials syringes IV solutions and parenteral nutrition products at the unit of use The initiative will help streamline...
BioDuro-Sundia and X-Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs
Monday, August 08, 2022BioDuroSundia an industryleading drug discovery development and commercial service CRDMO backed by Advent International and XChem a DEL technology pioneer in small molecule drug discovery jointly announced the launch of DNA Encoded Compound Library D...
TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial
Thursday, August 04, 2022TME Pharma NV a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment TME announced today that the first patient was enrolled and has received their first week of treatment in the...
